← Back to patent-cliff list
LT-002-158
Tier C — Watch / tradeLT-002-158
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IRAK4
Indications (approved)：Atopic dermatitis, Hidradenitis suppurativa, Rosacea, Acne vulgaris, 自身免疫疾病, Myelodysplastic syndrome, Acute myeloid leukaemia, Diffuse large B-cell lymphoma
Regional status
US
Phase I
2023-05-24
EU
-
China
Phase II
2025-06-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LT-002-158?
Approved indications include: Atopic dermatitis, Hidradenitis suppurativa, Rosacea, Acne vulgaris, 自身免疫疾病, Myelodysplastic syndrome, Acute myeloid leukaemia, Diffuse large B-cell lymphoma.
When does the LT-002-158 patent expire?
No public expiry year is available for LT-002-158 yet; this page updates once verified.
How do I get a quote for LT-002-158 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30